1. Home
  2. BCTX vs LSTA Comparison

BCTX vs LSTA Comparison

Compare BCTX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BriaCell Therapeutics Corp.

BCTX

BriaCell Therapeutics Corp.

HOLD

Current Price

$9.90

Market Cap

18.5M

Sector

Health Care

ML Signal

HOLD

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$1.98

Market Cap

20.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCTX
LSTA
Founded
2014
1980
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.5M
20.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCTX
LSTA
Price
$9.90
$1.98
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$40.00
$23.50
AVG Volume (30 Days)
57.6K
23.8K
Earning Date
12-11-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,070,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$380.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.00
$1.81
52 Week High
$106.50
$4.20

Technical Indicators

Market Signals
Indicator
BCTX
LSTA
Relative Strength Index (RSI) 44.95 43.52
Support Level $11.38 $1.85
Resistance Level $13.09 $2.16
Average True Range (ATR) 1.14 0.13
MACD 0.06 0.02
Stochastic Oscillator 30.12 46.87

Price Performance

Historical Comparison
BCTX
LSTA

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: